MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2016 International Congress

    Targeting PDE7 by the small molecule S14: A potential disease-modifying Parkinson�s disease therapy ready to start clinical trials

    A. Martinez, C. Gil, D. Lopez Ribas, E. Cunchillos, J. Domenech, M. Sarasa (Madrid, Spain)

    Objective: The main goal of this work is the regulatory chemical, pharmaceutical and toxicological development of S14, a new therapeutic class for the potential treatment…
  • 2016 International Congress

    The role and underlying mechanisms of BAG3 in regulating autophagy in PC12 cells

    Y.P. Yang, Y.L. Cao, C.J. Mao, F. Wang, L.F. Hu, C.F. Liu (Suzhou, People's Republic of China)

    Objective: To detect the role of Bcl-2-associated athanogene 3 (BAG3) in regulating autophagy in PC12 cells and explore the underlying mechanisms of it. Background: Increasing…
  • 2016 International Congress

    A computational model of iron transport between the blood circulation and the brain

    V. Tjendana-Tjhin, S. Mitchell, E.A. Milward, M.J. Chappell, J.F. Collingwood (Coventry, United Kingdom)

    Objective: To create a mechanistic computational model of iron transport between the circulation and brain, permitting in silico investigation of homeostatic regulation of iron at…
  • 2016 International Congress

    Progress in the development of small molecules based on the coumarin core as multifunctional neuroprotective agents

    M.J. Matos, D. Viña, F. Rodríguez-Enríquez, S. Vilar, L. Santana, E. Uriarte (Santiago de Compostela, Spain)

    Objective: Taking into account the background of our research group and the knowledge that MAO and ChE activity generates ROS that cause neuronal cell death,…
  • 2016 International Congress

    Identification of unique metabolite signatures in post-mortem DBS human tissue using LC-HRMS

    V. Vedam-Mai, S. Sternberg, M. Williams, T. Garrett, M.S. Okun (Gainesville, FL, USA)

    Objective: Metabolomics is applied to the study of metabolic as well as neurodegenerative diseases. We propose to utilize this technique to detect metabolic changes from…
  • 2016 International Congress

    Serum level of vitamin D3 in patients with neurodegenerative diseases compared to healthy adults and its correlation with the years spent from the initial diagnosis

    A.N. Taravari (Skopje, Macedonia)

    Objective: Vitamin D is an important factor responsible for many physiologic functions. Vitamin D deficiency is associated with increased risk of neurodegenerative disease. Background: The…
  • 2016 International Congress

    Neuronal nicotinamide-N-methyltransferase (NNMT) in Parkinson’s disease

    K. Schmeisser, A. Parker (Montreal, QC, Canada)

    Objective: Understanding the role of NNMT in initiation and progression of Parkinson's disease (PD). Background: 10-15% of all PD cases are caused by genetic factors,…
  • 2016 International Congress

    Creatine for patients with Parkinson’s disease: A meta-analysis

    A. Attia, H. Ahmed, M. Morsi, K. Awad, M. Elnenny, E. Ghanem, A. Negida (Cairo, Egypt)

    Objective: The aim of this systematic review and meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the efficacy of creatine for…
  • 2016 International Congress

    Dynamics in statin use, low density lipoprotein cholesterol levels and Parkinson’s disease. A population-based cohort study using big-data

    V. Rozani, N. Giladi, B. Elad, T. Gurevich, J. Tsamir, B. Hemo, C. Peretz (Petach Tikva, Israel)

    Objective: To evaluate the association between time-varying statin use and PD risk in a large-scale population-based study. Background: Statins have been shown to downregulate neuroinflammation,…
  • 2016 International Congress

    STEADY-PD III. A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease. Baseline characteristics of the enrolled cohort

    T. Simuni, K.M. Biglan, J. Lowell, K. Hodgeman, B. Greco, R. Rockhill, D. Oakes (Chicago, IL, USA)

    Objective: To evaluate the efficacy of isradipine 10 mg daily on PD disability. Background: Isradipine, a dihydropyridine calcium channel antagonist with excellent penetration of the…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley